Discovery of a Novel Series of Potent SHP2 Allosteric Inhibitors
Alessia Petrocchi, Alessandro Grillo, Luca Ferrante et al. · ACS Medicinal Chemistry Letters · 2023
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is the first reported nonreceptor oncogenic tyrosine phosphatase connecting multiple signal transduction cascades and exerting immunoinhibitory function through the PD-1 checkpoint receptor. As part of a drug discovery program aimed at obtaining novel allosteric SHP2 inhibitors, a series of pyrazopyrazine derivatives bearing an original bicyclo[3.1.0]hexane basic moiety on the left-hand side region of the molecule were identified. We report herein the discovery process, the in vitro pharmacological profile, and the early developability features of compound 25, one of the most potent members of the series.
Cited by 14 works. doi:10.1021/acsmedchemlett.3c00059 Open-access PDF
Authors
- Alessia Petrocchi
- Alessandro Grillo
- Pietro Randazzo
- Adolfo Prandi
- Marilenia De Matteo
- Costanza Iaccarino
- Monica Bisbocci
- Antonella Cellucci
- Cristina Alli
- Martina Nibbio
- Vincenzo Pucci
- Jérôme Amaudrut
- Christian Montalbetti
- Carlo Toniatti
- Romano Di Fabio
References
- Crystal Structure of the Tyrosine Phosphatase SHP-2
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
- Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies
- A comprehensive review of SHP2 and its role in cancer
- Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
- Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
- Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors